Research Analysts’ Recent Ratings Updates for Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical (NASDAQ: RARE) has recently received a number of price target changes and ratings updates:

• 8/21/2026 – Ultragenyx Pharmaceutical had its price target raised by Morgan Stanley from $67.00 to $74.00. They now have an “overweight” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $81.00 to $83.00. They now have a “buy” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Citigroup Inc. from $45.00 to $58.00. They now have a “buy” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Wells Fargo & Company from $45.00 to $46.00. They now have an “overweight” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Cantor Fitzgerald from $96.00 to $103.00. They now have an “overweight” rating on the stock.
• 8/10/2026 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
• 8/8/2026 – Ultragenyx Pharmaceutical was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/5/2026 – Ultragenyx Pharmaceutical had its price target lowered by Wells Fargo & Company from $47.00 to $45.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Ultragenyx Pharmaceutical had its price target lowered by Guggenheim from $43.00 to $35.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Ultragenyx Pharmaceutical was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/7/2026 – Ultragenyx Pharmaceutical had its price target raised by Royal Bank Of Canada from $35.00 to $40.00. They now have an “outperform” rating on the stock.
• 6/24/2026 – Ultragenyx Pharmaceutical was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $25.05, for a total transaction of $50,100.00. Following the sale, the director directly owned 21,095 shares of the company’s stock, valued at $528,429.75. This trade represents a 8.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Howard Horn sold 4,653 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $23.77, for a total value of $110,601.81. Following the completion of the transaction, the chief financial officer owned 105,689 shares in the company, valued at $2,512,227.53. The trade was a 4.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 8,552 shares of company stock valued at $207,455 over the last ninety days. 5.20% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.